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Background: This is a Phase I trial demonstrating safety and tolerability of intravaginal curcumin for future use in women with cervical neoplasia.
Objective: The objective of this study was to assess the safety, tolerability, and pharmacokinetics of intravaginal curcumin in healthy women.
Study design: We conducted a 3+3 dose-escalation Phase I trial in a group of women aged
18–45 years. Thirteen subjects were given one of four doses of curcumin powder (500 mg,
1,000 mg, 1,500 mg, and 2,000 mg) packed in gelatin capsules, which was administered intravaginally daily for 14 days. The primary end point for this study was safety based on severe
adverse events regarding laboratory toxicity, clinical findings, and colposcopic abnormalities.
We administered an acceptability questionnaire to assess product experience and attributes.
Results: No dose-limiting toxicities (0/13) were experienced (95% confidence interval: 0.0%–
22.8%) in this study. The pharmacokinetics data demonstrated that curcumin and curcumin
conjugates were not measurable in the serum and negligible in the urine of the study participants.
Although 23 adverse events occurred during the course of the trial, all events were grade I based
on the National Cancer Institute Common Terminology Criteria for Adverse Events Version 4.0
and were resolved by the end of the study in an average of 9 days. Fifty-six percent of the adverse
events were related to the study drug, which included genital pruritus (23% of subjects), vaginal
discharge (100%), vaginal dryness (15%), abnormal prothrombin (23%), and hypokalemia (8%).
Conclusion: Intravaginal curcumin was well tolerated by all subjects and safe. In this Phase I trial,
there were no severe adverse events observed at any of the administered dose levels. All adverse
events were grade I and did not result in early termination of the study. There was no evidence
of systemic absorption or significant local absorption of intravaginally administered curcumin.
Keywords: cervix, curcumin, intravaginal, safety, tolerability, neoplasia
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Cervical cancer is the fourth most common cancer worldwide with 85% of the global
burden occurring in developing countries.1 It is the leading cause of cancer-related
deaths among women in East Africa, Central America, and Southeast Asia with an estimated 528,000 women developing the disease in 2012 and 266,000 deaths.1–6 Women
in these countries are dying from the failure of treatment in a timely fashion to prevent
the progression of cervical dysplasia to cancer. The lack of surgical equipment and
trained clinicians who are able to perform routine surgical procedures (routine in most
of the world) is one of the main causes. In addition, current treatment modalities for
high-grade cervical intraepithelial neoplasia (CIN) are associated with complications
such as preterm labor, preterm delivery, and cervical incompetence.6,7 The advent of a
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medical therapeutic agent that is economical and sustainable
with a low side-effect profile may provide an alternative to
surgical or ablative management of disease since there is
normally a slow progression of high-grade CIN to cancer.
This study explores the safety of such an agent: curcumin
administered intravaginally in women.
Curcumin, a common ayurvedic medicinal agent, has been
shown, in oral doses, to have anticancer activity and cause
regression of premalignant lesions in several tissues including
the cervix.8 Several studies have demonstrated that curcumin
treatment alters human papillomavirus (HPV)-associated
molecular pathways in cancer cells and suppresses cervical
cancer growth by inhibiting the transcription of the oncoproteins
of HPV16 and restoring the expression of tumor suppressor
protein p53.9,10 In addition, it has been shown to downregulate
E6 and E7 oncoproteins in human cancer cell lines, inhibit
the expression of cancer promoting epidermal growth factor
receptor, and induce p53 expression in HPV-infected cells.11
However, oral curcumin has poor bioavailability, limiting
its ability to reach target tissues and organ systems at effective concentrations.12 However, in the past few years, some
investigators have taken the approach of delivering curcumin
via nanotechnology to increase its oral bioavailability in
healthy subjects and patients with cancer; demonstration of
effectiveness is still in its infancy.13,14 Thus, the development
of a noninvasive medical intervention that involves the application of curcumin directly into the vagina presents a novel
approach to the treatment of cervical dysplasia. Through an
intravaginal route, dysplastic cervical cells would be directly
targeted and the local dosing of curcumin would be easily
monitored and controlled.
Therefore, the purpose of this study was to evaluate the
safety, tolerability, and pharmacokinetics (PKs) of a potential
medical therapeutic herb, curcumin, delivered intravaginally
in women with no evidence of cervical intraepithelial lesions.
We hypothesized that women would tolerate intravaginal
curcumin with minimal to no adverse reactions, and that the
PK analysis would demonstrate low serum bioavailability
and low urinary excretion.

Patients and methods
Institutional Review Board and Food and
Drug Administration’s investigational new
drug application
This study was granted approval from the Grady Health
System Research Oversight Committee, Clinical Translational Research Committee, and the Emory institutional IRB
Committee. The Food and Drug Administration’s investiga-
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tional new drug number for this study is 103496 and the NCT
number is 01035580.

Study sample
Via convenience sampling strategies, we recruited 49 women
who were willing to participate and subsequently assessed for
the eligibility for this study. Following clinical screening of
these potential participants, we excluded 36 women from the
study due to their ineligibility based on the exclusion criteria.
The 13 women who met the eligibility criteria were enrolled
and provided their written informed consent to participate in
the study (Figure 1).
Eligibility criteria for this study included: who 1) were
identifying as female by birth (woman); 2) were in the age
group of 18–45 years; 3) had a negative Pap test at screening; 4) reported regular monthly menses (every 21–35 days)
or amenorrhea due to contraceptive use; 5) were willing to
provide a male sexual partner notification consent if currently sexually active; and 6) could read and write in English
and/or Spanish. All the study subjects were required to use
contraception during the study.
Exclusion criteria included: who had 1) a history of having
a total hysterectomy; 2) chronic medical conditions (including
HIV, diabetes, hypertension) or immunologic disorders; 3) a
history of cervical cancer; and 4) identified lacerations present on the cervix, vagina, or vulva at the time of screening.

Methodological approach
The study design used was a 3+3 dose escalation approach
(Figure 2).15 The maximum tolerated dose (MTD) was defined
as the highest curcumin dose with acceptable side effects
or dose-limiting toxicities (DLTs). For this study, the MTD
was defined as the highest curcumin dose level at which ≤1/6
patients developed DLTs. We selected the doses based on
Sabinsa, CURCUMIN C3 COMPLEX® use in several clinical
trials of which the curcumin is formulated into 500 mg capsules.16 Due to the safety concerns, we started with the lowest
dose and selected an upper bound of 2,000 mg expecting that
would be the highest tolerable dose based on the information
provided by the consulting gynecologists. The four capsules
of 500 mg would reach the 2,000 mg dose. More than 90%
of the gynecologists we surveyed prior to the clinical trial
inception reported concern about patient comfort and compliance with greater than four capsules.
DLT was defined as any event related to the study drug,
curcumin, based on the National Cancer Institute Common
Terminology Criteria for Adverse Events Version 4.0 as
category grade II or grade III or grade I lasting longer than
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Assessed for eligibility (n=49)

Enrolled (n=13)
Group 1
Allocated to 500 mg curcumin capsules (n=3)
• Received 500 mg curcumin capsules (n=3)

Allocation

Group 2
Allocated to 1,000 mg curcumin capsules (n=3)
• Received 1,000 mg curcumin capsules (n=3)
Group 3
Allocated to 1,500 mg curcumin capsules (n=3)
• Received 1,500 mg curcumin capsules (n=3)

Follow-up

Group 4
Allocated to 2,000 mg curcumin capsules (n=4)
• Received 2,000 mg curcumin capsules (n=4)
Lost to follow-up (n=0)
Discontinued curcumin capsules (n=3)
• n=1 at 1,000 mg dose (choose not to finish)
• n=2 at 2,000 mg dose (choose not to finish)

Analysis
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Enrollment

Excluded (n=36)
• Did not meet inclusion criteria (n=10)
• Refused to participate (n=18)
• Other reasons (n=8)

All the available data were analyzed for safety (n=13)

Figure 1 Study flow diagram.

Treat three patients at dose k

0 DLTs

1 DLT

Escalate to
dose k+1

Treat three more
patients at dose k

Return to the top of the
chart with dose k+1

1 DLT out
of six patients

>1 DLTs

>1 DLT out of
six patients

If six patients
already treated
at dose k–1

De-escalate to
dose k–1

If three patients already
treated at dose k–1

Treat three more
patients at dose k–1

Escalate to
dose k+1
Stop
study
Return to the top of the
chart with dose k+1

Figure 2 Traditional 3+3 dose escalation study design.
Notes: k indicates current dose examining throughout the study, k+1 indicates the dose higher than the current dose, k-1 indicates the dose lower than the current dose.
Garrett-Mayer E, Clinical Trials, Vol 3(1), pages 57–71, Copyright © 2006. Adapted by permission of SAGE Publications, Ltd.15
Abbreviation: DLT, dose-limiting toxicity.
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2 weeks in duration. DLT was the primary end point to be
summarized with a proportion and 95% confidence interval
(CI). For this reason, we did not calculate sample sizes and
did not perform any inference tests. As is standard for a
Phase I trial, the study had a very small sample size and is
descriptive (by design).

The initial screening of interested study participants was
completed by a study nurse. On day 0 (enrollment visit), each
participant had a clean catch urine analysis, hematology and
chemistry 8 panel, and speculum/pelvic examination by a
study clinician. Predose plasma and urine samples were
collected for PK studies to evaluate the local absorption.
The level of curcumin absorbed in the cervical tissues was
not performed in this study, and it will be evaluated in the
future studies. Wet prep was completed to test vaginal pH
and ascertain the presence of candida, bacterial vaginosis,
and trichomonas. A vaginal smear was air-dried for Gram’s
staining for Nugent’s score and Ansel’s criteria and used to
diagnosis bacterial vaginosis. The colposcopy examination
of the vulva, vagina, and cervix was conducted by qualified
women’s health clinicians. The colposcopic findings were
recorded in a study chart, and the colposcope digital images
were recorded and stored in a secured imaging database.
Colposcopy was also completed on day 7 and day 14 of the
study. The clinical and laboratory procedures are described
in Table 1.
After completing 7 days of intravaginal applications of
curcumin (day 7), each participant was admitted overnight to
the Grady satellite of the Atlanta Clinical and Translational
Science Institute Clinical Integrated Network for serial blood

Study procedures
In this trial, three subjects were to be treated at the lowest
dose: 500 mg curcumin capsules inserted intravaginally every
day for 14 days. If one DLT was observed at 500 mg, then
three more subjects were to be treated at 500 mg. If no DLT
occurred in the first cohort of three subjects, then the three
new subjects would proceed to insert 1,000 mg of curcumin
intravaginally every day for 14 days. The dose escalation
should continue per protocol until reaching the MTD.
The study drug, CURCUMIN C3 COMPLEX® Powder/
Curcuma longa (turmeric), was packaged in orange-colored
gelatin capsules, size 0, from Capsuline R and was supplied
by the Sabinsa corporation at no cost. The study drug was free
to all the study participants. Each gelatin capsule contained
500 mg of CURCUMIN C3 COMPLEX®. The capsules were
placed in a carefully labeled opaque container and maintained
at room temperature.

Table 1 Clinical and laboratory procedures performed in the dose-escalation study of intravaginal curcumin in healthy women
Clinical procedure

Screening

Day 0: enrollment

Day 7: intravaginal
insertion

Day 14: intravaginal
insertion

Written informed consent
Medical history, physical examination, demographic, and
clinical questionnaire
N. gonorrheae and C. trachomatis testing
Pap test and HPV testing
Urine sample collection for urinalysis at all visits; hCG and
urine toxicology screen at screening only
Blood sample collection for HIV EIA and Western blot,
RPR
Blood sample collection for CBC, chemistry, PT/PTT
Blood sample collection for plasma PK level and urine
drug studies
Pelvic examination, wet mount, vaginal pH, Gram stain,
KOH, whiff test
Colposcopy (day 0, 7, and 14 only)
Instruct on product insertion/observe first insertion
Distribute study product
Review study diary (day 7 and 14)
Record number of returned gelatin capsules
Complete data collection form
Acceptability questionnaire and focus group

X
X

X

X

X

X

X

X
X

X

X

X

X

X

X
X
X

X

X

X
X
X
X

X

X

X
X
X
X

X
X
X
X

Abbreviations: CBC, complete blood count; C. trachomatis, Chlamydia trachomatis; EIA, enzyme-linked immunosorbent assay; HPV, human papillomavirus; N. gonorrheae,
Neisseria gonorrheae; PK, pharmacokinetic; PT, prothrombin; PTT, partial thromboplastin time; RPR, rapid plasma reagin.
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and urine sampling to study the PK of intravaginal curcumin.
Based on the previous studies using similar intravaginal
products, the expected steady state of drug absorption should
have been achieved by day 7. Any symptoms described by the
participant since day 0 of the trial were transcribed into the
participant’s record. Vital signs, hematology and chemistry
8 panel, speculum examination with colposcopy, wet prep,
and a Gram stain were collected.
At the completion of the study, patients’ study diaries were
reviewed to ascertain compliance and to discuss the adverse
side effects. The remaining study capsules were counted and
compared with the patient’s study diary and report.
For pharmacokinetic sample collection, an indwelling
foley catheter was inserted immediately after colposcopic
examination to avoid contamination and to allow easy collection of urine samples. Intravenous access was obtained and
left in place for serial blood draws. Quality trained Clinical
Integrated Network personnel recorded the time of dosing and
postdose blood draws at the following times: 0 hour, 0.25 hours,
0.5 hours, 1 hour, 1.5 hours, 2 hours, 3 hours, 4 hours, 5 hours,
6 hours, 8 hours, and 12 hours. The collected blood was
centrifuged at 3,000 rpm for 10 minutes, and the serum was
separated and kept frozen until PK analysis. Urine samples
were collected at the same time points as the blood draws from
the foley catheter. The catheter was completely emptied after
each sampling. Urine volume for each collection was recorded,
and aliquots of 2 mL were stored and frozen until PK analysis.
For pharmacokinetic analysis, plasma and urine concentrations of curcumin and curcumin glucuronide/sulfate conjugates
were quantified by liquid chromatography coupled with tandem
mass spectrometry. For the quantification of curcumin, aliquots
of plasma or urine samples were spiked with the internal
standard (honokiol) and extracted with ethyl acetate prior to
liquid chromatography coupled with tandem mass spectrometry
analysis. For the quantification of curcumin conjugates, aliquots
of samples underwent enzymatic hydrolysis prior to ethyl
acetate extraction. Chromatographic separation was achieved
on a C18 column with a gradient of water and acetonitrile
consisting of 0.3% formic acid. Curcumin and the internal
standard were detected in the selected reaction monitoring mode
utilizing negative electrospray ionization. Linear calibration
curve was established over a curcumin concentration range
of 0.5–500 ng/mL when 0.5 mL of plasma or urine was used.
On day 14 of treatment, vital signs, blood work, speculum
examination, wet prep, Gram stain, and colposcopy were
completed. The participant’s study diary was reviewed to
ascertain the compliance and inquire about the adverse side

Open Access Journal of Clinical Trials 2017:9
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effects. These data were recorded in the patient’s chart. Any
remaining capsules were counted and compared with the
patient’s study diary. All the study participants were then
administered an acceptability questionnaire to complete at
the end of their study participation on day 14.
Outcome measures for safety data were based on
severe adverse effects regarding laboratory toxicity, severe
colposcopic abnormalities, and severe adverse clinical findings. Adverse side effects were coded, and the percentage of
patients experiencing that event was recorded. The clinical
symptoms measured included pelvic pain, genital pruritus,
genital pain, vaginal discharge, perianal ulcers, vaginal dryness, vaginitis, breakthrough bleeding, and decreased libido.
DLTs were summarized with a 95% CI using Wilson’s method
for a single sample.17
Colposcopic findings (present or absent) were described
for each dose at baseline, day 0, day 7, and day 14.

Acceptability assessment
Study materials were developed in English and Spanish.
Bilingual clinical staff and behavioral scientists reviewed
these documents to ensure their adequate readability and item
comprehension prior to administration. We determined
that the Flesch–Kincaid reading score met the acceptable
criteria of sixth to eighth grade reading level for our target
population.18,19
Acceptability was assessed by asking women if they
were comfortable using curcumin capsules and if they experienced any problems with the product. In addition to the
selected acceptability correlates, the questionnaire included
scale items designed to measure psychosocial indicators of
attitudes and perceptions surrounding their curcumin experience such as if they noticed curcumin after insertion and
after sex. Each scale item was measured by a 3–5-point Likert
scale (eg, 1, strongly disagree to 5, strongly agree), which
was designed to assign meaningful values to an underlying
continuum of ratings.20

Results
A total of 13 women meeting the eligibility criteria were
enrolled and completed the dose-escalation trial. The demographic profile of enrolled subjects was as follows: Hispanic/
Latino (15.4%), Asian (7.7%), African American (46.2%),
and Caucasian (30.8%); the mean age at the enrollment was
28.8 years. Three of the subjects had no partners, six were
living with a partner, and four were not living with their
partners (Table 2).
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Table 2 Baseline characteristics of healthy women enrolled in the study of intravaginal curcumin, overall and by curcumin dose (n=13)
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Characteristics
Ethnicity
Hispanic
Race
Asian
Black
Other
White
Partner status
No partner
Living with a partner
Not living with a partner
Age, mean (SD)

Overall (n=13)

500 mg (n=3)

1,000 mg (n=3)

1,500 mg (n=3)

2,000 mg (n=4)

2/13 (15.4%)

1/3 (33.3%)

1/3 (66.7%)

0/3 (0.0%)

0/4 (0.0%)

1/13 (7.7%)
6/13 (46.2%)
2/13 (15.4%)
4/13 (30.8%)

1/3 (33.3%)
0/3 (0.0%)
1/3 (33.3%)
1/3 (33.3%)

0/3 (0.0%)
1/3 (33.3%)
1/3 (33.3%)
1/3 (33.3%)

0/3 (0.0%)
2/3 (66.7%)
0/3 (0.0%)
1/3 (33.3%)

0/4 (0.0%)
3/4 (75.0%)
0/4 (0.0%)
1/4 (25.0%)

3/13 (23.1%)
6/13 (46.2%)
4/13 (30.8%)
28.8 (7.6)

0/3 (0.0%)
1/3 (33.3%)
2/3 (66.7%)
27.2 (10.4)

1/3 (33.3%)
1/3 (33.3%)
1/3 (33.3%)
28.2 (6.2)

1/3 (33.3%)
1/3 (33.3%)
1/3 (33.3%)
23.8 (2.9)

1/4 (25.0%)
3/4 (75.0%)
0/4 (0.0%)
34.0 (7.9)

Note: Data shown as number (%) or mean (SD).

The first study subject of the 2,000 mg dose had only 2 mL
of serum and urine collected at each time point during the
PK component of the study. Therefore, an additional study
subject was added in the 2,000 mg dose to assure adequate
collection of serum and urine for the required 12 subjects
for the PK analysis. The number of subjects starting therapy
at each dose is shown in Figure 1. No DLTs were observed
at 500 mg, 1,000 mg, 1,500 mg, and 2,000 mg. An MTD
was not identified. The study was stopped at 2,000 mg due
to funding limitations.

Pelvic examination
No pelvic examination abnormalities were found with the
exception of one vulvar abnormality and one cervical abnormality present since the time of screening. These abnormalities
did not exclude either of the patients from the enrollment. Pelvic examination test results found one subject (dose: 1,500 mg)
with an abnormal wet mount consistent with bacterial vaginosis
at day 7 which was not treated and resolved spontaneously by
day 14. Two subjects at day 0 (dose: 1,000 mg and 1,500 mg)
had yeast detected on KOH slide. However, these subjects
denied clinical symptoms and were not treated. On day 7,
no evidence of yeast was found on the examination for both
subjects. On day 14, two subjects were found to have yeast
vaginitis (dose: 500 mg and 1,500 mg). These two subjects
did not exhibit any clinical symptoms when contacted after
48 hours of completing the study. The most common urogenital
symptoms found during the pelvic examination were genital
pruritis, vaginal discharge, and vaginal dryness.

Genital pruritis
No subjects reported genital pruritis during the screening and
day 0 visits. However, three subjects (23%) reported pruritis
on day 7; one at the 500 mg dose and the remaining two
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subjects at the 1,500 mg dose. One subject (dose: 1,500 mg)
also had genital pruritis at day 14.

Vaginal discharge
One subject presented with vaginal discharge at day 0, upon
the application of first dose (dose: 1,000 mg). All the subjects
reported vaginal discharge on day 7 and day 14.

Vaginal dryness
Two subjects (15.4%) reported vaginal dryness at day 7 and
day 14. The subjects who reported vaginal dryness at day 7
were taking the 500 mg and 1,500 mg doses. The subjects
reporting vaginal dryness at day 14 were taking the 1,000 mg
and 1,500 mg dose.

Colposcopy examination
No abnormal colposcopy results were found during the
course of the study. Colposcopic findings investigated were
erythema, edema, leukoplakia, petechiae, ecchymosis, peeling, ulceration, abrasion, and laceration.

Laboratory results
There were no abnormal laboratory results greater than grade
I abnormality. Positive dipstick urinalysis results were found
in one subject at screening (dose: 500 mg), two subjects
at day 0 (dose: 500 mg), and one subject at day 14 (dose:
1,000 mg). No study subject was diagnosed with a urinary
tract infection. Three subjects (25%) had an intermediate
Nugent score at day 7, one subject at the 500 mg dose, and
two at the 1,500 mg dose. Three subjects (23.1%) also had an
intermediate result at day 14 (one subject each at the 500 mg,
1,500 mg, and 2,000 mg dose). No study subjects were found
to have a Nugent score on Gram stain eligible for bacterial
vaginosis (Nugent score >7).
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Adverse events
Twenty-three adverse events occurred in 13 subjects during
the course of the trial, six events in each of the following
groups: 500 mg dose, 1,500 mg dose, and 2,000 mg dose, and
five events in the 1,000 mg dose group (Table 3). The adverse
events fell into five categories: genital pruritis (23% of subjects), vaginal discharge (100%), vaginal dryness (23%),
abnormal prothrombin (23%), and hypokalemia (8%). All
events were grade I, and no DLTs were experienced. Fiftysix percent of the events were definitely related to the study
drug. None of the events had any implication for the study,
and no events required additional action. All events were
resolved by the end of the study in an average of 8.7 days.

Pharmacokinetic data
PK analysis was performed only in the 2,000 mg study population (n=4). There were no detectable levels of curcumin
or its conjugated metabolites in any of the serum samples
collected from the 2,000 mg dose group. However, curcumin
and its metabolites were detectable in urine collected from
the 2,000 mg dose group. The total amount of curcumin and
its conjugated metabolites in urine collected up to 12 hours
post-dose was 0–17.5 µg and 0–0.5 µg, respectively, <0.001%
of the dose applied.

Acceptability questionnaire data
Fifty-four percent (n=7/13) of the subjects rated the intravaginal application of curcumin as easy or very easy, regardless
of the dosage (Table 4). Seventy-seven percent of the study
subjects (n=10/13) denied any problems with the product.
The majority (69%, n=9) of the study participants denied any
symptoms of irritation. However, 84% of women (n=11/13)
disliked the color of the curcumin, and the majority found it
was too messy. All the study subjects agreed they would recommend this product to women as a way to prevent cervical

precancerous disease from turning into cancer, if approved
as safe and effective (100%, n=13).

Discussion
Curcumin is an inexpensive naturally occurring agent which
employs multiple mechanisms of action that can alter HPVassociated molecular pathways.9–11 Curcumin appears to
target key cell signaling pathways at multiple levels including
oncogenes (E6 and E7), inflammatory enzymes (COX-2), and
transcription factors (NF-kβ and AP-1).21–24 In high-risk HPV
cervical cell lines, it induces apoptosis by primarily inhibiting
the expression of E7.10 In light of high-risk HPV subtypes,
16 and 18 being largely responsible for high-grade cellular
transformation in the cervix. Curcumin’s potential role in the
prevention of cervical cancer would be its ability to inhibit the
expression of HPV oncogenes E6/E7, leading to the restoration of p53 and Rb tumor suppressor gene expression.9,10,25
In this trial, we sought to evaluate the safety, tolerability,
and PKs of intravaginal curcumin in healthy young women.
The results of this dose-escalation trial demonstrated safety
and tolerability up to a maximum dose of 2,000 mg per day
for a 14-day treatment. We observed no clinical or hematologic toxicities higher than grade I during the trial. There
were no pelvic or colposcopic abnormalities caused by the
study drug during the trial period. The PK data demonstrated
that curcumin and its conjugates were not measurable in the
serum and negligible in the urine of the study participants.
Similar adverse events such as vulvovaginal pruritus were
also seen in recent publications using curcumin cream for
HPV infection of the cervix.26
Our study identified that the most common symptom
observed was vaginal discharge that commenced following the intravaginal insertion. This discharge persisted
with continued usage of the study drug in which the
participants noted as an inconvenience. Yet, the vaginal

Table 3 Frequency of adverse events and the frequency and percentage of healthy women with adverse events found during pelvic
examination or laboratory toxicities during the 2 weeks of curcumin treatment
Adverse event
DLTa
Genital pruritic
Vaginal discharge
Vaginal dryness
Abnormal PTb
Hypokalemiac

Overall (n=13)

500mg (n=3)

1,000 mg(n=3)

1,500 mg (n=3)

AE (Pat) %

AE (Pat) %

AE (Pat) %

AE (Pat) %

2,000 mg (n=4)
AE (Pat) %

0 (0) 0.0%
4 (3) 23.1%
13 (13) 100%
2 (2) 15.4%
3 (3) 23.1%
1 (1) 7.7%

0 (0) 0.0%
2 (1) 33.3%
3 (3) 100%
1 (1) 33.3%
0 (0) 0.0%
0 (0) 0.0%

0 (0) 0.0%
0 (0) 0.0%
3 (3) 100%
0 (0) 0.0%
2 (2) 66.7%
0 (0) 0.0%

0 (0) 0.0%
2 (2) 66.7%
3 (3) 100%
1 (1) 33.3%
0 (0) 0.0%
0 (0) 0.0%

0 (0) 0.0%
0 (0) 0.0%
4 (4) 100%
0 (0) 0.0%
1 (1) 25.0%
1 (1) 25.0%

Notes: aDLT was defined as any event related to the study drug “curcumin” based on the National Cancer Institute CTCAE Version 4.0 as category grade II or grade III or
grade I lasting longer than 2 weeks in duration. bDefined as >1.0 × ULN. cDefined as 5.0 mEq/L or higher.
Abbreviations: AE, adverse event; CTCAE, Common Terminology Criteria for Adverse Events; DLT, dose-limiting toxicity; Pat, patients; PT, prothrombin; ULN, upper
limit of normal.
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Table 4 Results from acceptability questionnaire administered to 13 healthy women after using intravaginal curcumin for 2 weeks,
overall and by curcumin dose
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Questionnaire responses
Noticed curcumin powder after insertion
Noticed curcumin powder after sex
Had problems with the product
Curcumin powder gave symptoms of irritation
Could smell the curcumin powder
Describe the smell of the curcumin powder
Neutral
Unpleasant
Rate the curcumin powder’s color
Neutral
Disliked
Disliked a lot
Curcumin stained my underwear
Strongly agree
Somewhat agree
I am comfortable using curcumin powder
Strongly agree
Somewhat agree
Neutral
Somewhat disagree
Rate the ease of insertion of the curcumin gelatin capsules
Very easy
Easy
Neutral
Difficult
The curcumin powder was too messy
Strongly agree
Somewhat agree
Somewhat disagree
Strongly disagree
I felt the curcumin powder increased my sexual pleasure
Neutral
Somewhat disagree
Strongly disagree

500 mg

1,000 mg

1,500 mg

2,000 mg

n (%)

n (%)

n (%)

n (%)

n (%)

11/13 (84.6%)
3/13 (23.1%)
3/13 (23.1%)
4/13 (30.8%)
2/13 (15.4%)

2/3 (66.7%)
1/3 (33.3%)
1/3 (33.3%)
1/3 (33.3%)
0/3 (0.0%)

3/3 (100%)
1/3 (33.3%)
1/3 (33.3%)
1/3 (33.3%)
0/3 (0.0%)

3/3 (100%)
0/3 (0.0%)
0/3 (0.0%)
2/3 (66.7%)
1/3 (33.3%)

3/4 (75.0%)
1/4 (25.0%)
1/4 (25.0%)
0/4 (0.0%)
1/4 (25.0%)

12/13 (92.3%)
1/13 (7.75)

3/3 (100%)
0/3 (0.0%)

3/3 (100%)
0/3 (0.0%)

3/3 (100%)
0/3 (0.0%)

3/4 (75.0%)
1/4 (25.0%)

2/13 (15.4%)
4/13 (30.85)
7/13 (53.9%)

0/3 (0.0%)
2/3 (66.75)
1/3 (33.3%)

0/3 (0.0%)
0/3 (0.0%)
3/3 (100%)

1/3 (33.3%)
1/3 (33.3%)
1/3 (33.3%)

1/4 (25.0%)
1/4 (25.0%)
2/4 (50.0%)

9/13 (69.2%)
4/13 (30.8%)

3/3 (100%)
2/3 (66.7%)

3/3 (100%)
0/3 (0.0%)

0/3 (0.0%)
1/3 (33.3%)

1/4 (25.0%)
1/4 (25.0%)

4/13 (30.9%)
5/13 (38.5%)
2/13 (15.4%)
2/13 (15.4%)

1/3 (33.3%)
1/3 (33.3%)
1/3 (33.3%)
0/3 (0.0%)

0/3 (0.0%)
1/3 (33.3%)
1/3 (33.3%)
1/3 (33.3%)

2/3 (66.7%)
1/3 (33.3%)
0/3 (0.0%)
0/3 (0.0%)

1/4 (25.0%)
2/4 (50.0%)
0/4 (0.0%)
1/4 (25.0%)

3/13 (23.1%)
4/13 (30.8%)
4/13 (30.8%)
2/13 (15.4%)

0/3 (0.0%)
0/3 (0.0%)
2/3 (66.7%)
1/3 (33.3%)

1/3 (33.3%)
2/3 (66.7%)
0/3 (0.0%)
0/3 (0.0%)

1/3 (33.3%)
0/3 (0.0%)
1/3 (33.3%)
1/3 (33.3%)

1/4 (25.0%)
2/4 (50.0%)
1/4 (25.0%)
0/4 (0.0%)

6/13 (46.2%)
5/13 (38.5%)
1/13 (7.7%)
1/13 (7.7%)

1/3 (33.%)
2/3 (66.7%)
0/3 (0.0%)
0/3 (0.0%)

3/3 (100%)
0/3 (0.0%)
0/3 (0.0%)
0/3 (0.0%)

0/3 (0.0%)
3/3 (100%)
0/3 (0.0%)
0/3 (0.0%)

2/4 (50.0%)
0/4 (0.0%)
1/4 (25.0%)
1/4 (25.0%)

7/13 (53.9%)
5/13 (38.5%)
1/13 (7.7%)

1/3 (33.3%)
2/3 (66.7%)
0/3 (0.0%)

2/3 (66.7%)
1/3 (33.3%)
0/3 (0.0%)

2/3 (66.7%)
1/3 (33.3%)
0/3 (0.0%)

2/4 (50.0%)
1/4 (25.0%)
1/4 (25.0%)

discharge resolved without intervention once the drug was
discontinued. At the completion of the trial, all the participants agreed that the delivery of curcumin intravaginally
at all the study protocol dosages was tolerable and that
they would recommend it to women for the treatment of
cervical disease.
The safety and tolerability of intravaginally administered curcumin for potential use in the treatment of women
with cervical dysplasia are evidenced by this trial. The low
costs of curcumin could make this medical therapy even
more attractive in the US as well as developing and lowresource countries. Other studies are currently focused on
the development and implementation of injectable medical
therapies to treat high-grade cervical dysplasia. However,
intravaginal curcumin capsules stored at room temperature
may be more affordable than any injectable medication
8
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which may require expensive, specialized preparation
and storage.
Although we were not able to measure the amount of
drug absorbed locally by inserting the curcumin capsules
intravaginally, colposcopic evaluations during the treatment
course evidenced that the cervix was adequately coated with
the active ingredient of the investigational drug (Figure 3).
In addition, our patient population did not include women
who were postmenopausal. Therefore, we were not able to
observe whether this age group would have incured more
vaginal dryness and pruritus. However, it is less likely that
this age group will receive intravaginal curcumin for the treatment of cervical dysplasia in an effort to preserve fertility.
They are more likely to be treated with surgical resection via
loop electrical excisional procedure or hysterectomy for the
management of their cervical dysplasia.
Open Access Journal of Clinical Trials 2017:9
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Figure 3 Intravaginal curcumin on the cervix.

Limitations
One of the limitations of this study was that the MTD was
not reached and 2,000 mg is most likely an underestimation
of the MTD. It may be prudent in the future trials to consider
challenging this dosage especially for efficacy trials. A recent
four-arm Phase II trial comparing vaginal Basant cream
(curcumin based), curcumin capsules, vaginal placebo cream,
and placebo capsules demonstrated higher HPV clearance
rates in the Basant cream arm and the curcumin capsule arm
compared with the placebo groups.26 The results of this trial
show even more promise for the efficacy of curcumin given
that the maximum dose used was only 500 mg in the vaginal
capsules.26 Our trial clearly demonstrates that the MTD can
be upward of 2,000 mg.

Conclusion
This Phase I study found that intravaginal curcumin application resulted in minimal side effects and a safe pharmacokinetic profile. Yet, the product will need to improve its
product attributes (ie, color and messiness) to improve its
acceptability profile. Such modifications may encourage
its use as a potential treatment option for the treatment
of cervical dysplasia. However, with its multitude of antiinflammatory and anti-carcinogenic properties, future clinical
studies may reflect that curcumin is an ideal compound to
use for the treatment of cervical dysplasia.
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